Filing Details

Accession Number:
0001181431-12-041391
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-07-19 20:07:03
Reporting Period:
2012-07-17
Filing Date:
2012-07-19
Accepted Time:
2012-07-19 20:07:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1382911 Orexigen Therapeutics Inc. OREX Pharmaceutical Preparations (2834) 651178822
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1380022 Michael Narachi C/o Orexigen Therapeutics, Inc.
3344 N. Torrey Pines Court, Suite 200
La Jolla CA 92037
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-07-17 124,238 $1.66 124,238 No 4 M Direct
Common Stock Disposition 2012-07-17 124,238 $7.66 0 No 4 S Direct
Common Stock Acquisiton 2012-07-17 25,762 $1.70 25,762 No 4 M Direct
Common Stock Disposition 2012-07-17 25,762 $7.66 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2012-07-17 124,238 $0.00 124,238 $1.66
Common Stock Stock Option (right to buy) Disposition 2012-07-17 25,762 $0.00 25,762 $1.70
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,761,562 2021-07-24 No 4 M Direct
1,774,238 2021-06-09 No 4 M Direct
Footnotes
  1. The exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2012.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2012.
  3. 1/48th of the total number of shares of stock subject to the option (rounded down to the next whole number of shares) (which option is referred to in this Form 4 as the "Replacement Grant") shall vest on the same day of each one-month period of the reporting person's service as an employee, director or consultant following July 25, 2011, so that all of the shares of the stock subject to the option shall be vested on July 25, 2015, subject to the reporting person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
  4. Not applicable.
  5. 1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest and become exercisable on the same day of each month after June 10, 2011, so that all of the shares of the stock subject to the option shall be vested in full on June 10, 2015, subject to the reporting person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.